Cargando…

Immune-Checkpoint Blockade Therapy in Lymphoma

Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present on cytotoxic T cells, trigger inhibitory signalin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuzume, Ayumi, Chi, SungGi, Yamauchi, Nobuhiko, Minami, Yosuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432396/ https://www.ncbi.nlm.nih.gov/pubmed/32751706 http://dx.doi.org/10.3390/ijms21155456

Ejemplares similares

Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
por: Eguchi, Motoki, et al.
Publicado: (2020)

Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors
por: Ikeda, Daisuke, et al.
Publicado: (2022)

Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports
por: Yuda, Junichiro, et al.
Publicado: (2021)

The Immuno-Oncology and Genomic Aspects of DNA-Hypomethylating Therapeutics in Acute Myeloid Leukemia
por: Urabe, Akiko, et al.
Publicado: (2023)

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma
por: Lin, Adam Yuh, et al.
Publicado: (2022)

Emerging Immunotherapy for Acute Myeloid Leukemia
por: Tabata, Rikako, et al.
Publicado: (2021)

Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia
por: Arai, Hironori, et al.
Publicado: (2022)

Update on checkpoint blockade therapy for lymphoma
por: Kline, Justin, et al.
Publicado: (2015)

Acquired Resistance to Immune Checkpoint Blockade Therapies
por: Zhao, Xianda, et al.
Publicado: (2020)

The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018)

Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy
por: Cremolini, Chiara, et al.
Publicado: (2021)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review
por: Perdikis-Prati, Sarah, et al.
Publicado: (2023)

Immune checkpoint blockade therapy for bladder cancer treatment
por: Kim, Jayoung
Publicado: (2016)

Microbial biomarkers for immune checkpoint blockade therapy against cancer
por: Adachi, Keishi, et al.
Publicado: (2018)

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
por: Wang, Hao, et al.
Publicado: (2019)

Neutrophils in the era of immune checkpoint blockade
por: Faget, Julien, et al.
Publicado: (2021)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia
por: Chi, Sung-Gi, et al.
Publicado: (2022)

Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
por: Shin, Min Hwa, et al.
Publicado: (2020)

Gilteritinib Affects the Selection of Dominant Clones in Clonal Hematopoiesis: Sequential Genetic Analysis of an FLT3-ITD Positive AML Patient with Long-Term Gilteritinib Therapy
por: Katagiri, Seiichiro, et al.
Publicado: (2023)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

Predictive biomarkers for tumor immune checkpoint blockade
por: Tong, Mengting, et al.
Publicado: (2018)

Rethinking immune checkpoint blockade: ‘Beyond the T cell’
por: Liu, Xiuting, et al.
Publicado: (2021)

PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
por: Tobin, Joshua W. D., et al.
Publicado: (2021)

Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade
por: Ho, Rachel L. Y., et al.
Publicado: (2021)

Gastric Cancer in the Era of Immune Checkpoint Blockade
por: Figueroa-Protti, Lucía, et al.
Publicado: (2019)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
por: Zhang, Na, et al.
Publicado: (2020)

An immunomodulatory signature of responsiveness to immune checkpoint blockade therapy
por: Shen, Hongru, et al.
Publicado: (2020)

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
por: Swart, Maarten, et al.
Publicado: (2016)

Metabolic predictors of response to immune checkpoint blockade therapy
por: Shorer, Ofir, et al.
Publicado: (2023)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
por: Gong, Jun, et al.
Publicado: (2018)

Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs
por: Drakes, Maureen L., et al.
Publicado: (2020)

Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
por: Xiao, Qingyang, et al.
Publicado: (2020)

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
por: Macherla, Shravanti, et al.
Publicado: (2018)

Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma
por: Choi, Changhoon, et al.
Publicado: (2019)

Prospects for combining immune checkpoint blockade with PARP inhibition
por: Li, Anping, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o7g3d41dpr0spls7qgomggh6ls